We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Immunome Stock Up 32% in a Month: Here's What You Should Know
Read MoreHide Full Article
Key Takeaways
Immunome said that the FDA accepted varegacestat's NDA for treating adults with desmoid tumors.
IMNM expects an FDA decision by April 28, 2027, and plans an EMA filing by the end of 2026.
Immunome's pipeline also includes IM-1021, IM-3050 and IM-1617 in early-stage development.
Shares of Immunome (IMNM - Free Report) have witnessed a sharp increase over the past month, primarily driven by the growing investor confidence in the company’s lead asset, varegacestat, and broader clinical progress.
IMNM’s Price Performance
Shares of Immunome have rallied 31.6% in the past month compared with the industry’s increase of 7.7%.
Image Source: Zacks Investment Research
Earlier this week, the FDA accepted Immunome’s new drug application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor, for the treatment of adults with desmoid tumors.
With the FDA accepting the NDA for review, a decision from the regulatory agency is expected on April 28, 2027.
In April 2026, Immunome filed the NDA for varegacestat to treat adults with desmoid tumors. The company plans to submit a marketing authorization application to the European Medicines Agency for varegacestat by the end of 2026.
Desmoid tumors are aggressive, non-metastatic soft tissue tumors. Although they do not metastasize, desmoid tumors are associated with a significantly high recurrence rate following surgical resection.
More on IMNM’s Varegacestat & Other Pipeline Updates
The NDA for varegacestat was based on data from the phase III RINGSIDE study, which evaluated the candidate in patients with progressing desmoid tumors.
The registrational study met its primary endpoint of improving progression-free survival compared with placebo, demonstrating a statistically significant and clinically meaningful 84% reduction in the risk of disease progression or death. The study also met all key secondary endpoints.
A potential approval of varegacestat would give Immunome its first marketed product and establish a commercial revenue stream. This would mark a significant milestone for the company and could serve as a key catalyst for the stock.
Besides varegacestat, Immunome is developing IM-1021 in an early-stage study for treating participants with B-cell lymphoma. The company’s early-stage pipeline also includes IM-3050 and IM-1617, which are being developed to treat certain types of solid tumors.
Last month, the company dosed the first patient in a phase I study evaluating IM-1617, a potential first-in-class antibody-drug conjugate (ADC) for treating patients with advanced solid tumors.
Immunome’s recent development with varegacestat, as well as its expanding pipeline, including IM-1021 and several ADC programs, indicates long-term growth potential.
Over the past 60 days, estimates for Amarin’s 2026 loss per share have narrowed from $15.20 to 65 cents. Over the same period, loss per share estimates for 2027 have narrowed from $13.00 to 51 cents. AMRN shares have increased 8.3% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 50.02%.
Over the past 60 days, estimates for PTC Therapeutics’ 2026 bottom line have improved from a loss of $1.40 per share to earnings of 78 cents. Over the same time, estimates for 2027 earnings per share have risen from $1.20 to $2.11. PTCT stock has risen 17.9% year to date.
PTC Therapeutics’ earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average negative surprise being 115.67%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $1.94 to $3.02, while estimates for 2027 have increased from $3.79 to $4.92 during the same time. LQDA shares have surged 136.2% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.
View the Zacks #1 Rank List
Image: Bigstock
Immunome Stock Up 32% in a Month: Here's What You Should Know
Key Takeaways
Shares of Immunome (IMNM - Free Report) have witnessed a sharp increase over the past month, primarily driven by the growing investor confidence in the company’s lead asset, varegacestat, and broader clinical progress.
IMNM’s Price Performance
Shares of Immunome have rallied 31.6% in the past month compared with the industry’s increase of 7.7%.
Image Source: Zacks Investment Research
Earlier this week, the FDA accepted Immunome’s new drug application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor, for the treatment of adults with desmoid tumors.
With the FDA accepting the NDA for review, a decision from the regulatory agency is expected on April 28, 2027.
In April 2026, Immunome filed the NDA for varegacestat to treat adults with desmoid tumors. The company plans to submit a marketing authorization application to the European Medicines Agency for varegacestat by the end of 2026.
Desmoid tumors are aggressive, non-metastatic soft tissue tumors. Although they do not metastasize, desmoid tumors are associated with a significantly high recurrence rate following surgical resection.
More on IMNM’s Varegacestat & Other Pipeline Updates
The NDA for varegacestat was based on data from the phase III RINGSIDE study, which evaluated the candidate in patients with progressing desmoid tumors.
The registrational study met its primary endpoint of improving progression-free survival compared with placebo, demonstrating a statistically significant and clinically meaningful 84% reduction in the risk of disease progression or death. The study also met all key secondary endpoints.
A potential approval of varegacestat would give Immunome its first marketed product and establish a commercial revenue stream. This would mark a significant milestone for the company and could serve as a key catalyst for the stock.
Besides varegacestat, Immunome is developing IM-1021 in an early-stage study for treating participants with B-cell lymphoma. The company’s early-stage pipeline also includes IM-3050 and IM-1617, which are being developed to treat certain types of solid tumors.
Last month, the company dosed the first patient in a phase I study evaluating IM-1617, a potential first-in-class antibody-drug conjugate (ADC) for treating patients with advanced solid tumors.
Immunome’s recent development with varegacestat, as well as its expanding pipeline, including IM-1021 and several ADC programs, indicates long-term growth potential.
Immunome, Inc. Price
Immunome, Inc. price | Immunome, Inc. Quote
IMNM’s Zacks Rank & Other Stocks to Consider
Immunome currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are Amarin (AMRN - Free Report) , PTC Therapeutics ((PTCT - Free Report) ) and Liquidia Corporation ((LQDA - Free Report) ), each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Amarin’s 2026 loss per share have narrowed from $15.20 to 65 cents. Over the same period, loss per share estimates for 2027 have narrowed from $13.00 to 51 cents. AMRN shares have increased 8.3% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 50.02%.
Over the past 60 days, estimates for PTC Therapeutics’ 2026 bottom line have improved from a loss of $1.40 per share to earnings of 78 cents. Over the same time, estimates for 2027 earnings per share have risen from $1.20 to $2.11. PTCT stock has risen 17.9% year to date.
PTC Therapeutics’ earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average negative surprise being 115.67%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $1.94 to $3.02, while estimates for 2027 have increased from $3.79 to $4.92 during the same time. LQDA shares have surged 136.2% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.